Companies › KalVista Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 4; Immunology; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| sebetralstat (KVD900) Plasma kallikrein inhibitor | KLKB1 | Phase 4 | Hereditary Angioedema | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07654829 | sebetralstat (KVD900) | Phase 4 | Hereditary Angioedema | Immunology | Nov 2027 |
Kyowa Kirin BioCryst Pharmaceuticals ADARx Pharmaceuticals Pharvaris Netherlands DiaMedica Therapeutics
Pharvaris Netherlands BioCryst Pharmaceuticals Biopharma Plasma Psoriasis Research Institute of Guangzhou Triple Hair
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.